VRTX: Vertex Pharmaceuticals Incorporated Stock

by  •  • Comments Off on VRTX: Vertex Pharmaceuticals Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 101,600.37
Enterprise Value ($M) 90,382.07
Book Value ($M) 17,580.40
Book Value / Share 68.02
Price / Book 5.78
NCAV ($M) 8,994.40
NCAV / Share 34.80
Price / NCAV 11.30

Profitability (mra)
Return on Invested Capital (ROIC) 0.20
Return on Assets (ROA) 0.19
Return on Equity (ROE) 0.25

Liquidity (mrq)
Quick Ratio 3.78
Current Ratio 3.99

Balance Sheet (mrq) ($M)
Current Assets 14,144.20
Assets 22,730.20
Liabilities 5,149.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 9,869.20
Operating Income 4,318.80
Net Income 3,619.60
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 3,537.30
Cash from Investing -3,141.70
Cash from Financing -562.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G/A Capital World Investors 10.00 17.31
02-13 13G/A Vanguard Group Inc 8.65 3.41
02-09 13G/A Fmr Llc 5.04 -27.38
01-25 13G BlackRock Inc. 8.50 -9.74

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 128,960 784,054 16.45
2024-04-17 137,326 636,268 21.58
2024-04-16 84,351 513,172 16.44
2024-04-15 272,650 565,821 48.19

(click for more detail)

Similar Companies
VIR – Vir Biotechnology, Inc. VIRX – Viracta Therapeutics, Inc.
VOR – Vor Biopharma Inc. VTRS – Viatris Inc.
VTYX – Ventyx Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io